Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup

Allergan PLC never really left the market for biopharmaceutical mergers and acquisitions after it entered into a $160bn merger agreement with Pfizer Inc., but now that the deal has been called off the company is free to buy assets large and small that fit its "growth pharma" focus.

More from Neurological

More from Therapy Areas